NCT06319170View on ClinicalTrials.gov

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

PHASE1CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

March 28, 2024

Primary Completion Date

January 15, 2025

Study Completion Date

January 15, 2025

Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
DRUG

Olanzapine Extended Release

Powder and vehicle for injectable suspension

DRUG

Olanzapine

IntraMuscular Injection

Trial Locations (5)

30030

Teva Investigational Site 15728, Decatur

30331

Teva Investigational Site 15729, Atlanta

33024

Teva Investigational Site 15727, Hollywood

90720

Teva Investigational Site 15730, Los Alamitos

08053

Teva Investigational Site 15726, Marlton

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT06319170 - Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder | Biotech Hunter | Biotech Hunter